Sanjay Nilapwar works currently as Senior Research Investigator in Large Molecules development group of Incyte Corporation, Wilmington, Delaware and is also part of platform large molecules CMC development team. In current position, which has held from 2017, he looks after transitioning of mAb molecules from candidate drug to development and manufacturing stage, encompassing cycle 1 to 3 processes and purification development, technology transfer and related CMC aspects including filing IND/IMPDs. In 2013 he started working for Spirogen, prior to its takeover by Medimmune, where he worked on development of site-specific and stochastic PBD based conjugation at research scale, stability and analytical assay development and was instrumental in setting up large scale ADC purification lab within Medimmune. He started working on protein conjugates at Piramal Lifescience by conjugating a range of therapeutic drugs including cytotoxics and radiolabeled chelates to therapeutic mAbs for Targeted therapies. He has more than 12 years of experience in large molecule/conjugates purification development and has published 10 papers and written couple of book chapters. He regularly speaks at conferences and chairs conference session. Dr. Nilapwar has earned his PhD in Molecular Biology and Biophysics from UCL, London and M. Pharm in Pharmaceutical Chemistry from Mumbai University.